ESMO 2022

Hand cooling and compression both effective in…

Dose-dense therapy is beneficial for all patients

QoL and longterm toxicity

Roadmap for the adjuvant setting

Dose dense is better

DD is the champion!

Simple and cheap surgical technique may impact survival…

Endocrine response in eBC

Long-term data on dose density therapy in chemotherapy

My highlights of ESMO22

Consolidating data from prospective studies

Immuntherapy only for low risk patients?

Reduction of peripheral neuropathy with taxane therapy

Schéma dose-dense bénéfique pour toutes les patientes

Il vincitore e’ il dose dense!!

Rosta i tania technika chirurgiczna może wpływać na…

Chłodzenie rąk i terapia kompresyjna skutecznie…

I miei punti salienti di ESMO22

Unmeet needs and my wishes for 2022!

Tailoring Adjuvant Therapy

Who needs Chemo? Who does not? Is OFS plus endocrine…

Dose-dense CT Efficacy confirmed in the Nodal+ ER+…

DATA: Still open questions on the optimal duration of…

Status update - adjuvant IO. Are TILs prognostic?

OS not significant, but re-assuring new data

SG is a novel treatment option for HR+/HER2- disease

Survival benefit from SG in mBC

Discontinued development

Endocrine-based therapy may prove more effective than…

HER2+ and still without chemotherapy

Update on biomarkers on ADCs of the DAISY trial

ADC after ADC - is there any orientation?

New treatment option for heavily pre-treated patients…

CDK4/6i could be an option for selected ER+/HER2+…

TROPiCS-02 highlights

Another option for heavily pre-treated HR+ advanced…

Survival benefit in endocrine sensitive patients

Exciting data, but Phase 3 studies are needed

New data re-inforces SG as a new option pre-treated…

The third in the bunch

More therapy options for patients with HR+, HER2+…

Sacituzumab govitecan for everybody!

VEX has no place in chemotherapy of metastatic breast…

Interim analysis shows promising data on Abema in the…

Negative and yet positive?!

Nuove opzioni di trattamento personalizzate per…

I miei punti salienti di ESMO22

Sopravvivenza globale nello studio MONARCH3

TROPiCS-02 highlights

Nouvelle option thérapeutique pour les patientes…

SG come nuova opzione di cura Per pazienti con tumore…

Nouvelles données des analyses expolratoires dans…

Sacituzumab Govitecan: Un farmaco per tutte?

Leczenie zaawansowanych raków „potrójnie dodatnich”…

Interim OS Data & PFS Update for Abemaciclib hint…

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd…

ADC efficacy in perspective: SG overall survival…

SERDs: equal PFS benefit vs. endocrine therapy;…

CDK4/6i plus Trastuzumab – a possible chemo-free option…

Pollution and lung cancer - one mechanism revealed

Liquid biopsy monitoring of EGFR-mutant lung cancer…

ADAURA revisited

Is OS really needed?

Neoadjuvant strategies for PD-L1 < 1 %

Concurrent preoperative IO/CRT in early lung cancer

Osimertinib stays standard adjuvant

INCREASE - to good to be true?

Long term follow-up of ADAURA trial

Window for treatment selection

Osimertinib - curing or delaying relapse?

Double IO + chemoradiotherapy - is it feasible in…

Osimertinib: una cura o ritarda la ripresa di malattia?

Osimertinib bleibt Standard adjuvant

Langzeitdaten ADAURA

Liquid biopsie monitoring van patiënten met een EGFR…

Pollution et cancer du poumon - un mécanisme mis en…

Dubbele immunotherapie plus chemoradiotherapie - is het…

ADAURA revisited

Important data on borderline resectable patients

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib vs. Docetaxel in mKRAS G12C

One more brick in the KRAS G12C wall

Induction chemoimmunotherapy in borderline…

New immunotherapy options for pts. ineligible to 1st…

If you don't look, vou don't find - once you found it,…

Duration of immunotherapy : Stop and go strategy for…

Emerging IO mono options in the first line

Liquid biopsy monitoring in treatment decisions

Can we finally treat poor prognostic patients with…

The journey at KRAS G12C continues

A new step in treatment of KRAS G12C mutant NSCLC

Preview on lung cancer highlights

Real-world data on Atezolizumab

DESTINY-Lung02 - better than the original?

5-year data on survival under immunotherapy

Sotorasib - a new standard of care?

Immunotherapy in unfit population? Perhaps...

Chemoimmunotherapy - improvement of survival after 5…

New therapy combination after progression on 1L…

Atezolizumab better than vinorelbin in reduced…

Cemiplimab beyond progression?

Pneumonitis and T-DXd

5 years of chemoimmunotherapy: solid grounded

Sotorasib: sweet and sour results

Poseidon and STK11/KEAP

Is shorter immunotherapy equally effective and less…

5-year update on 1st line chemoimmunotherapy

HER2 - the next actionable mutation in lung cancer?

Question about timing and duration of immunotherapy…

Une nouvelle étape dans le traitement du CBNPC KRAS…

Durée de l'immunothérapie : stratégie Stop and Go pour…

Kunnen we eindelijk patiënten met een slechte prognose…

Sotorasib vs. Docetaxel bei mKRAS G12C

Neue Option der IO-Therapie in der Erstlinie

Données de vie réelle avec l’atezolizumab

Pneumonitis und T-DXd

Kürzere Immuntherapie gleich effektiv aber weniger…

Poseidon und STK11/KEAP

Resultados Agridulces de Sotorasib

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Se non lo cerchi non lo troiv. Quando lo hai trovato,…

Les études incontournables à l’ESMO 2022

Cemiplimab beyond progression?

Kann IO pausiert werden?

Liquid Biopsy Monitoring zur Therapiesteuerung

Un mattone in piu' nel muro del KRAS G12C

Una nueva opción de tratamiento con IO en pacientes no…

5-Jahresüberleben mit Immuntherapie

5 Jahre Chemo-Immuntherapie: starker Effekt

IO-IO neoadjuvant bei PD-L1 neg.

Atezo besser als Vino bei PS2-3

Die Reise bei KRAS G12C geht weiter

Chimio-immunothérapie - amélioration de la survie après…

Neue Therapiekombination in der Resistenz nach…

A positive study! With a question mark?

New strategies in immunotherapy

Novel data and long-term efficacy of chemo-IO in mNSCLC

Two negative studies question adjuvant approach in RCC

Place of triplet therapy

Adjuvant CPI in kidney cancer – 2 phase III trials with…

New combo - triplet therapy for kidney cancer

News in terms of adjuvant

Adjuvant Immuntherapy in kidney cancer

Exciting data for high-risk patients: is this the start…

More questions being raised

Brief highlights about RCC & urothelial cancer from…

Immune-based peri-operative treatment in RCC: What went…

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Inmunoterapia adyuvante en el cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer…

Immunomodulation in combination with…

Shedding light on TKI/Checkpointinhibitor combinations

Adjuvant immunotherapy options in RCC - what do we…

EV + Pembro with excellent response rates

EV + pembrolizumab in cisplatin-ineligible patients

Biomarker exploration in urothelial cancer - finding…

Promising data, but beware of toxicity

ADCs - a possible therapeutic approach

In older vulnerable - less is more

Radicals - ADT & Radiotherapy

QoL data from ARASENS triplet therapy study mHRPC

Update on the PROpel study

ADT + ENZA better choice than monotherapy

Combination of olaparib leads to promising results

Cabazitaxel better tolerated in elderly men

Triplet therapy with darolutamide in prostate cancer

Length of hormone therapy after radiation

IO + PARP without benefit in the allcomer situation

Genetic testing before PARP therapy is useful

Should intensification of ADT be considered in…

Biomarker data for better patients selection

IM arbiraterone decanoate might demonstrate superior…

PSA at 8-months as a biomarker

Further evaluation of PSA correlates

Livskvalitetsuppföljning i ARASENS studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Positive results, but testing not that simple

Modern Imaging is the new standard

PSA response after triplet therapy: What is the impact…

Which men benefit from adding ADT?

New group of substances for rare diseases

TILs - Fashion is the eternal return of the old

Novel approach von Biontech towards Cancer – game…

Addition of CPI to Radiochemotherapy in LA-HNSCC?

IAP-inhibition – comming game changer in LA-HNSCC…